Abstract
Abstract
This Research Letter summarizes all updates to the 2019 Guidelines through September 2023, including: endorsement of the 2021 Opportunistic Infections guidelines for HIV+ or immunosuppressed patients; clarification of use of human papillomavirus testing alone for patients undergoing observation for cervical intraepithelial neoplasia 2; revision of unsatisfactory cytology management; clarification that 2012 guidelines should be followed for patients aged 25 years and older screened with cytology only; management of patients for whom colposcopy was recommended but not completed; clarification that after treatment for cervical intraepithelial neoplasia 2+, 3 negative human papillomavirus tests or cotests at 6, 18, and 30 months are recommended before the patient can return to a 3-year testing interval; and clarification of postcolposcopy management of minimally abnormal results.References
Articles referenced by this article (9)
Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines.
J Low Genit Tract Dis, (2):132-143 2020
MED: 32243308
Response to Letter to the Editor Regarding: 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors.
J Low Genit Tract Dis, (4):426 2020
MED: 32732648
2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors.
J Low Genit Tract Dis, (2):102-131 2020
MED: 32243307
Factors associated with reduced accuracy in Papanicolaou tests for patients with invasive cervical cancer.
Cancer Cytopathol, (9):694-701 2014
MED: 24888458
CIN 2/3 and cervical cancer in an organised screening programme after an unsatisfactory or a normal Pap smear: a seven-year prospective study of the Norwegian population-based screening programme.
J Med Screen, (2):70-76 2004
MED: 15153321
Risk-Based Cervical Consensus Guidelines: Methods to Determine Management if Less Than 5 Years of Data Are Available.
J Low Genit Tract Dis, (3):195-201 2022
MED: 35763610
Erratum: 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors.
J Low Genit Tract Dis, (4):330-331 2021
MED: 34542089
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors.
Obstet Gynecol, (4):829-846 2013
MED: 23635684
Does the interval between papanicolaou tests influence the quality of cytology?
Cancer, (3):133-138 2005
MED: 15822121
Citations & impact
Impact metrics
Article citations
Machine Learning Prediction of Residual and Recurrent High-Grade CIN Post-LEEP.
Cancer Manag Res, 16:1175-1187, 06 Sep 2024
Cited by: 0 articles | PMID: 39258245 | PMCID: PMC11385362
Risk factors for residual lesions after total hysterectomy in patients with high-grade cervical intraepithelial neoplasia.
BMC Womens Health, 24(1):369, 24 Jun 2024
Cited by: 0 articles | PMID: 38915002 | PMCID: PMC11194937
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
The clinician's view: role of human papillomavirus testing in the American Society for Colposcopy and Cervical Pathology Guidelines for the management of abnormal cervical cytology and cervical cancer precursors.
Arch Pathol Lab Med, 127(8):950-958, 01 Aug 2003
Cited by: 22 articles | PMID: 12952506
Update on ASCCP consensus guidelines for abnormal cervical screening tests and cervical histology.
Am Fam Physician, 80(2):147-155, 01 Jul 2009
Cited by: 39 articles | PMID: 19621855
Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less.
J Low Genit Tract Dis, 17(5 suppl 1):S69-77, 01 Apr 2013
Cited by: 35 articles | PMID: 23519308 | PMCID: PMC3616505
Risk of Cervical Dysplasia After Colposcopy Care and Risk-Informed Return to Population-Based Screening: A Systematic Review.
J Obstet Gynaecol Can, 42(5):607-624, 01 Nov 2019
Cited by: 2 articles | PMID: 31679914
Review
Funding
Funders who supported this work.
Intramural NIH HHS (1)
Grant ID: ZIA CP010124